HomeIRWD • NASDAQ
Ironwood Pharmaceuticals, Inc.
$8.78
Mar 28, 1:17:11 PM GMT-4 · USD · NASDAQ · Disclaimer
StockUS listed securityUS headquartered
Previous close
$8.62
Day range
$8.59 - $9.01
Year range
$8.07 - $15.70
Market cap
1.37B USD
Avg Volume
6.56M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Financials
Income Statement
Revenue
Net income
(USD)Dec 2023Y/Y change
Revenue
117.55M9.66%
Operating expense
63.17M122.50%
Net income
-1.09M-102.22%
Net profit margin
-0.92-102.02%
Earnings per share
0.00-100.00%
EBITDA
4.22M-93.85%
Effective tax rate
105.75%
Total assets
Total liabilities
(USD)Dec 2023Y/Y change
Cash and short-term investments
92.15M-85.96%
Total assets
471.07M-57.20%
Total liabilities
817.37M82.39%
Total equity
-346.30M
Shares outstanding
156.53M
Price to book
-3.90
Return on assets
1.86%
Return on capital
2.37%
Net change in cash
(USD)Dec 2023Y/Y change
Net income
-1.09M-102.22%
Cash from operations
35.83M-54.74%
Cash from investing
-4.19M-15,611.11%
Cash from financing
-50.90M-1,914.11%
Net change in cash
-19.31M-123.54%
Free cash flow
3.64M-92.45%
About
Ironwood Pharmaceuticals, Inc is a publicly traded pharmaceutical company. It was originally called Microbia, Inc. Microbia was founded by postdocs from the lab of Gerald Fink at the Whitehead Institute to commercialize approaches that had been developed in the lab to improve industrial fermentation of fungi, to genetically engineer them to produce secondary metabolites more efficiently or to produce new ones as leads for drug discovery or as products for use in industry, and to identify drug targets in fungi for antifungal drug discovery. In 2002 the company hired John Talley to lead their antifungal drug discovery efforts, which at the time were focused on identifying small molecules that could inhibit fungal invasins, along with Mark Currie who had also worked at Searle division of Monsanto with Talley, and then had gone to Sepracor, and also Richard Bailey, who had run Monsanto's nutritional business. Currie directed the efforts that led to the discovery of linaclotide, which was based on an enterotoxin produced by some strains of Escherichia coli that cause traveler’s diarrhea. By 2004 the company had raised $99M and was preparing a Phase I trial for linaclotide. Wikipedia
Founded
1998
Employees
267
Discover more
You may be interested in
This list is generated from recent searches, followed securities, and other activity. Learn more

All data and information is provided “as is” for personal informational purposes only, and is not intended to be financial advice nor is it for trading purposes or investment, tax, legal, accounting or other advice. Google is not an investment adviser nor is it a financial adviser and expresses no view, recommendation or opinion with respect to any of the companies included in this list or any securities issued by those companies. Please consult your broker or financial representative to verify pricing before executing any trades. Learn more
People also search for
Search
Clear search
Close search
Google apps
Main menu